B of A Securities Reiterates Buy Rating on Tyra Biosciences
B of A Securities maintains its buy rating on Tyra Biosciences, setting a $42 price target.
Key Points
- B of A Securities reiterated its buy rating on Tyra Biosciences, Inc. (TYRA) on June 10, 2026, with a price target of $42.
- Tyra Biosciences, trading at $26.99, has a market cap of approximately $1.61 billion, with a forward P/E ratio indicating it isn't profitable yet.
- Insider buying activity was reported on May 28, 2026, with multiple insiders purchasing 13,160 shares each.
On June 10, 2026, B of A Securities reiterated its buy rating on Tyra Biosciences, Inc. (NasdaqGS: TYRA) with a price target of $42. The stock is currently trading at $26.99.
Other Institutional Activity in Tyra Biosciences
FMR LLC significantly increased its holdings in Tyra Biosciences, adding 7,735,085 shares to reach a total of 7,747,648 shares valued at about $296.7 million. Meanwhile, Janus Henderson Group PLC expanded its position by 955,147 shares, now holding 3,890,589 shares worth approximately $148.9 million. Farallon Capital Management LLC also boosted its investment by 1,514,000 shares, bringing its total to 3,580,818 shares, valued at $137.1 million.
Tyra Biosciences Stock Snapshot
Shares of NasdaqGS:TYRA traded near $26.99. Tyra Biosciences has a market cap of approximately $1.61 billion. The stock has a 52-week low of $8.98 and a high of $40.65, with a 50-day moving average of $33.63 and a 200-day moving average of $25.86. Its current ratio of 20.49 and quick ratio of 20.05 suggest strong liquidity, while a debt-to-equity ratio of 1.47 indicates manageable leverage.
Insider Buying and Selling at Tyra Biosciences, Inc.
Several insiders, including Susan Moran, Jake Simson, Adele Gulfo, and Robert More, each purchased 13,160 shares on May 28, 2026. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On June 10, 2026, B of A Securities maintained its buy rating on Tyra Biosciences with a $42 price target. Guggenheim initiated coverage with a buy rating and a $54 target on April 15, 2026. Canaccord Genuity also initiated coverage with a buy rating and a $50 target on April 6, 2026. The consensus among analysts is a strong buy, with a mean price target of $51.60 across 11 opinions.
About Tyra Biosciences
Tyra Biosciences, Inc. is a biotechnology company based in Carlsbad, California. It focuses on developing precision medicines for diseases related to fibroblast growth factor receptor (FGFR) biology. The company uses its SNÅP platform to design drugs for oncology and genetically defined conditions. Tyra's lead product, FGFR3, is in trials for metastatic urothelial carcinoma. Other products in development include TYRA-300 for skeletal conditions and TYRA-200 for intrahepatic cholangiocarcinoma.
Bottom Line
Tyra Biosciences continues to attract attention from analysts and investors. B of A Securities' reiterated buy rating and $42 price target reflect confidence in the company's prospects. With significant insider buying and strong institutional interest, Tyra remains a company to watch. Investors should note that 13F filings are historical and may not reflect current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.